141 related articles for article (PubMed ID: 31313970)
21. Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits.
Pang X; Li J; Pi J; Qi D; Guo P; Li N; Wu Y; Liu Z
Pharm Dev Technol; 2018 Mar; 23(3):231-239. PubMed ID: 28488447
[TBL] [Abstract][Full Text] [Related]
22. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial.
Quimby JM; Brock WT; Moses K; Bolotin D; Patricelli K
J Feline Med Surg; 2015 Aug; 17(8):692-7. PubMed ID: 25336450
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone.
Hay Kraus BL
Vet Anaesth Analg; 2013 Jan; 40(1):28-34. PubMed ID: 23082784
[TBL] [Abstract][Full Text] [Related]
24. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of single doses of maropitant citrate in adult horses.
Berryhill EH; Knych H; Edman JM; Magdesian KG
J Vet Pharmacol Ther; 2019 Jul; 42(4):487-491. PubMed ID: 31190332
[TBL] [Abstract][Full Text] [Related]
26. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
McLaurin E; Cavet ME; Gomes PJ; Ciolino JB
Optom Vis Sci; 2018 Mar; 95(3):264-271. PubMed ID: 29461408
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of maropitant citrate in Rhode Island Red chickens (Gallus gallus domesticus) following subcutaneous administration.
Mones AB; Petritz OA; Knych HK; Sadar MJ; Thomson AE; Guzman DS
J Vet Pharmacol Ther; 2022 Sep; 45(5):495-500. PubMed ID: 35734891
[TBL] [Abstract][Full Text] [Related]
28. A comparison between maropitant and metoclopramide for the prevention of morphine-induced nausea and vomiting in dogs.
Lorenzutti AM; Martín-Flores M; Litterio NJ; Himelfarb MA; Invaldi SH; Zarazaga MP
Can Vet J; 2017 Jan; 58(1):35-38. PubMed ID: 28042152
[TBL] [Abstract][Full Text] [Related]
29. Effects of maropitant citrate or acepromazine on the incidence of adverse events associated with hydromorphone premedication in dogs.
Claude AK; Dedeaux A; Chiavaccini L; Hinz S
J Vet Intern Med; 2014; 28(5):1414-7. PubMed ID: 25146756
[TBL] [Abstract][Full Text] [Related]
30. Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy.
Corrêa JMX; Niella RV; Oliveira JNS; Silva Junior AC; Marques CSDC; Pinto TM; Silva EBD; Beier SL; Silva FL; Lavor MSL
Acta Vet Scand; 2021 Nov; 63(1):49. PubMed ID: 34838084
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of maropitant citrate after oral administration of multiple doses in adult horses.
Berryhill EH; Knych H; Chigerwe M; Edman J; Magdesian KG
J Vet Pharmacol Ther; 2020 May; 43(3):282-287. PubMed ID: 32067245
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
Benchaoui HA; Cox SR; Schneider RP; Boucher JF; Clemence RG
J Vet Pharmacol Ther; 2007 Aug; 30(4):336-44. PubMed ID: 17610407
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs.
Sedlacek HS; Ramsey DS; Boucher JF; Eagleson JS; Conder GA; Clemence RG
J Vet Pharmacol Ther; 2008 Dec; 31(6):533-7. PubMed ID: 19000276
[TBL] [Abstract][Full Text] [Related]
34. Effect of dosing interval on efficacy of maropitant for prevention of hydromorphone-induced vomiting and signs of nausea in dogs.
Hay Kraus BL
J Am Vet Med Assoc; 2014 Nov; 245(9):1015-20. PubMed ID: 25313812
[TBL] [Abstract][Full Text] [Related]
35. The effect of maropitant on intraoperative isoflurane requirements and postoperative nausea and vomiting in dogs: a randomized clinical trial.
Swallow A; Rioja E; Elmer T; Dugdale A
Vet Anaesth Analg; 2017 Jul; 44(4):785-793. PubMed ID: 28844293
[TBL] [Abstract][Full Text] [Related]
36. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
[TBL] [Abstract][Full Text] [Related]
37. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs.
Ramsey DS; Kincaid K; Watkins JA; Boucher JF; Conder GA; Eagleson JS; Clemence RG
J Vet Pharmacol Ther; 2008 Dec; 31(6):538-43. PubMed ID: 19000277
[TBL] [Abstract][Full Text] [Related]
39. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Cartagena-Albertus JC; Engel Manchado J; Moise A; Moya García S; Montoya Alonso JA
Am J Vet Res; 2019 Jun; 80(6):601-606. PubMed ID: 31140850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
